EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function

Sophie Bromberger iD, Yuliia Zadorozhna, Julia Maria Ressler iD, Silvio Holzner iD, Arkadiusz Nawrocki, Nina Zila iD, Alexander Springer iD, Martin Røssel Larsen iD, Klaudia Schossleitner iD

Life Science Alliance · 2024

DOI: 10.26508/lsa.202402671 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Sophie Bromberger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors, Melanoma, Signal Transduction. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vienna Science and Technology Fund, Comprehensive Cancer Center Vienna, European Molecular Biology Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but effects of the inhibitors in this cell type are unknown. Hence, we aimed to characterize responses to approved BRAFi for melanoma in the vascular endothelium. We showed that clinically approved BRAFi induced a paradoxical activation of endothelial MAPK signaling. Moreover, phosphoproteomics revealed distinct sets of off-targets per inhibitor. Endothelial barrier function and junction integrity were impaired upon treatment with vemurafenib and the next-generation dimerization inhibitor PLX8394, but not with dabrafenib or encorafenib. Together, these findings provide insights into the surprisingly distinct side effects of BRAFi on endothelial signaling and functionality. Better understanding of off-target effects could help to identify molecular mechanisms behind AEs and guide the continued development of therapies for BRAF-mutant melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsMelanomaSignal TransductionVemurafenibHumansOximesSulfonamidesEndothelium, VascularImidazolesEndothelial CellsMAP Kinase Signaling SystemCarbamatesHuman Umbilical Vein Endothelial CellsCell Line, TumorMutation

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, humanVemurafenibOximesdabrafenibSulfonamidesImidazolesencorafenibCarbamates

Autor:innen und Institutionen

  • Department of Dermatology, Medical University of Vienna, Vienna, Austria.
  • Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
  • University of Applied Sciences FH Campus Wien, Division of Biomedical Science, Vienna, Austria.
  • Department of Pediatric Surgery, Medical University of Vienna, Vienna, Austria.
  • Department of Dermatology, Medical University of Vienna, Vienna, Austria klaudia.schossleitner@meduniwien.ac.at.

ORCID-Profile: Sophie Bromberger, Julia Maria Ressler, Silvio Holzner, Nina Zila, Alexander Springer, Martin Røssel Larsen, Klaudia Schossleitner

Förderung

  • Vienna Science and Technology Fund
  • Comprehensive Cancer Center Vienna
  • European Molecular Biology Organization
  • City of Vienna, Cancer Research Fund

Zitieren

APA

Bromberger, S., Zadorozhna, Y., Ressler, J. M., Holzner, S., Nawrocki, A., Zila, N., Springer, A., Røssel Larsen, M., & Schossleitner, K. (2024). Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. Life Science Alliance. https://doi.org/10.26508/lsa.202402671

Vancouver

Bromberger S, Zadorozhna Y, Ressler JM, Holzner S, Nawrocki A, Zila N, et al. Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. Life Science Alliance. 2024. doi:10.26508/lsa.202402671

BibTeX
@article{Bromberger2024,
  author = {Bromberger, Sophie and Zadorozhna, Yuliia and Ressler, Julia Maria and Holzner, Silvio and Nawrocki, Arkadiusz and Zila, Nina and Springer, Alexander and Røssel Larsen, Martin and Schossleitner, Klaudia},
  title = {Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function},
  journal = {Life Science Alliance},
  year = {2024},
  doi = {10.26508/lsa.202402671}
}
Kostenlos starten →